Contemporary Management Of Uterine Clear Cell Carcinoma
Publication Date: November 1, 2019
Last Updated: March 14, 2022
Conclusions
1. UCCC has a higher propensity for extrauterine spread and warrants extended or comprehensive surgical staging, although sentinel lymph node dissection may be a reasonable alternative to complete lymphadenectomy.
2. UCCC is less responsive to chemotherapy when compared to other types of endometrial cancer.
3. We recommend consideration of chemotherapy but also recommend development of clinical trials to further evaluate the role of chemotherapy for early stage UCCC. A.B. Olawaiye, C.A. Leath III / Gynecologic Oncology 155 (2019) 365e373 371
4. Vaginal cuff brachytherapy may offer a benefit in outcomes for women with early stage UCCC.
5. Patients with advanced stage UCCC should be offered adjuvant therapy, although evidence for UCCC-specific adjuvant therapy is lacking.
6. In spite of a higher probability of receiving adjuvant therapy than other types of uterine cancer, both PFS and OS for UCCC appears to be inferior thus further solidifying UCCC as an aggressive histology with unique and largely unknown profile.
7. Future clinical trials should continue to allow UCCC enrollment with this and other high risk histologies utilized as a stratification variable.
2. UCCC is less responsive to chemotherapy when compared to other types of endometrial cancer.
3. We recommend consideration of chemotherapy but also recommend development of clinical trials to further evaluate the role of chemotherapy for early stage UCCC. A.B. Olawaiye, C.A. Leath III / Gynecologic Oncology 155 (2019) 365e373 371
4. Vaginal cuff brachytherapy may offer a benefit in outcomes for women with early stage UCCC.
5. Patients with advanced stage UCCC should be offered adjuvant therapy, although evidence for UCCC-specific adjuvant therapy is lacking.
6. In spite of a higher probability of receiving adjuvant therapy than other types of uterine cancer, both PFS and OS for UCCC appears to be inferior thus further solidifying UCCC as an aggressive histology with unique and largely unknown profile.
7. Future clinical trials should continue to allow UCCC enrollment with this and other high risk histologies utilized as a stratification variable.
Recommendation Grading
Overview
Title
Contemporary Management Of Uterine Clear Cell Carcinoma
Authoring Organization
Society of Gynecologic Oncology
Publication Month/Year
November 1, 2019
Last Updated Month/Year
March 16, 2023
Document Type
Guideline
External Publication Status
Published
Country of Publication
US
Document Objectives
This SGO review is updated with all relevant, published information since 2009 considered clinically important for management of uterine clear cell carcinoma.
Target Patient Population
Patients with uterine clear cell carcinoma
Inclusion Criteria
Female, Adolescent, Adult, Older adult
Health Care Settings
Ambulatory, Hospice, Hospital, Operating and recovery room, Outpatient
Intended Users
Nurse, nurse practitioner, physician, physician assistant
Scope
Assessment and screening, Diagnosis, Management, Treatment
Diseases/Conditions (MeSH)
D002583 - Uterine Cervical Neoplasms, D018262 - Adenocarcinoma, Clear Cell, D018227 - Sarcoma, Clear Cell, D014594 - Uterine Neoplasms
Keywords
oncology, uterine neoplasms, clear cell carcinoma